Epidemiologia e terapia delle infezioni micotiche nell'ospite immunocompromesso, con particolare riguardo al ruolo delle formulazioni lipidiche di amfortericina B

Translated title of the contribution: Epidemiology and therapy of mycotic infections in immunocompromised patients, with particular attention to the role of lipid formulations of amphotericin B

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The extensive use of antifungal prophylaxis may have played a role in the increased incidence of invasive fungal infections in immunocompromised patients. Amphotericin B remains the antifungal agent with the broadest spectrum of action available and is thus the standard treatment for immunocompromised patients with proven or suspected fungal infections, especially aspergillosis. However, its potential for nephrotoxicity limits its usefulness. Lipid formulations of amphotericin B may allow therapy to be administered with reduced renal toxicity. Three different lipid formulations of amphotericin B are currently available. These compounds have different pharmacokinetics properties and usually achieve higher serum and/or tissue concentrations than amphotericin B. At present, there are no studies comparing the lipid formulations with each other and only a few randomized trials comparing them with conventional amphotericin B. However, a number of open clinical trials and compassionate-use protocols suggest that lipid-based forms of amphotericin B can achieve good response rates with minimal toxicity in patients with a variety of invasive mycoses, including those who have proved refractory or intolerant to previous therapy with conventional amphotericin B. Unfortunately, the cost of these compounds remains very high and may represent a limiting factor to their use.

Original languageItalian
Pages (from-to)545-557
Number of pages13
JournalRecenti Progressi in Medicina
Volume90
Issue number10
Publication statusPublished - Oct 1999

Fingerprint

Immunocompromised Host
Amphotericin B
Epidemiology
Lipids
Infection
Therapeutics
Compassionate Use Trials
Aspergillosis
Mycoses
Antifungal Agents
Pharmacokinetics
Clinical Trials
Kidney
Costs and Cost Analysis
Incidence
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{bc15dee61a014eb4bdfc065bd0caffbf,
title = "Epidemiologia e terapia delle infezioni micotiche nell'ospite immunocompromesso, con particolare riguardo al ruolo delle formulazioni lipidiche di amfortericina B",
abstract = "The extensive use of antifungal prophylaxis may have played a role in the increased incidence of invasive fungal infections in immunocompromised patients. Amphotericin B remains the antifungal agent with the broadest spectrum of action available and is thus the standard treatment for immunocompromised patients with proven or suspected fungal infections, especially aspergillosis. However, its potential for nephrotoxicity limits its usefulness. Lipid formulations of amphotericin B may allow therapy to be administered with reduced renal toxicity. Three different lipid formulations of amphotericin B are currently available. These compounds have different pharmacokinetics properties and usually achieve higher serum and/or tissue concentrations than amphotericin B. At present, there are no studies comparing the lipid formulations with each other and only a few randomized trials comparing them with conventional amphotericin B. However, a number of open clinical trials and compassionate-use protocols suggest that lipid-based forms of amphotericin B can achieve good response rates with minimal toxicity in patients with a variety of invasive mycoses, including those who have proved refractory or intolerant to previous therapy with conventional amphotericin B. Unfortunately, the cost of these compounds remains very high and may represent a limiting factor to their use.",
keywords = "Drug resistance, Emerging fungal pathogens, Invasive fungal infections, Lipid formulations of amphotericin B, Neoplastic disease",
author = "Claudio Viscoli and Elio Castagnola",
year = "1999",
month = "10",
language = "Italian",
volume = "90",
pages = "545--557",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "10",

}

TY - JOUR

T1 - Epidemiologia e terapia delle infezioni micotiche nell'ospite immunocompromesso, con particolare riguardo al ruolo delle formulazioni lipidiche di amfortericina B

AU - Viscoli, Claudio

AU - Castagnola, Elio

PY - 1999/10

Y1 - 1999/10

N2 - The extensive use of antifungal prophylaxis may have played a role in the increased incidence of invasive fungal infections in immunocompromised patients. Amphotericin B remains the antifungal agent with the broadest spectrum of action available and is thus the standard treatment for immunocompromised patients with proven or suspected fungal infections, especially aspergillosis. However, its potential for nephrotoxicity limits its usefulness. Lipid formulations of amphotericin B may allow therapy to be administered with reduced renal toxicity. Three different lipid formulations of amphotericin B are currently available. These compounds have different pharmacokinetics properties and usually achieve higher serum and/or tissue concentrations than amphotericin B. At present, there are no studies comparing the lipid formulations with each other and only a few randomized trials comparing them with conventional amphotericin B. However, a number of open clinical trials and compassionate-use protocols suggest that lipid-based forms of amphotericin B can achieve good response rates with minimal toxicity in patients with a variety of invasive mycoses, including those who have proved refractory or intolerant to previous therapy with conventional amphotericin B. Unfortunately, the cost of these compounds remains very high and may represent a limiting factor to their use.

AB - The extensive use of antifungal prophylaxis may have played a role in the increased incidence of invasive fungal infections in immunocompromised patients. Amphotericin B remains the antifungal agent with the broadest spectrum of action available and is thus the standard treatment for immunocompromised patients with proven or suspected fungal infections, especially aspergillosis. However, its potential for nephrotoxicity limits its usefulness. Lipid formulations of amphotericin B may allow therapy to be administered with reduced renal toxicity. Three different lipid formulations of amphotericin B are currently available. These compounds have different pharmacokinetics properties and usually achieve higher serum and/or tissue concentrations than amphotericin B. At present, there are no studies comparing the lipid formulations with each other and only a few randomized trials comparing them with conventional amphotericin B. However, a number of open clinical trials and compassionate-use protocols suggest that lipid-based forms of amphotericin B can achieve good response rates with minimal toxicity in patients with a variety of invasive mycoses, including those who have proved refractory or intolerant to previous therapy with conventional amphotericin B. Unfortunately, the cost of these compounds remains very high and may represent a limiting factor to their use.

KW - Drug resistance

KW - Emerging fungal pathogens

KW - Invasive fungal infections

KW - Lipid formulations of amphotericin B

KW - Neoplastic disease

UR - http://www.scopus.com/inward/record.url?scp=0032829079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032829079&partnerID=8YFLogxK

M3 - Articolo

VL - 90

SP - 545

EP - 557

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 10

ER -